Skip to content
Issue / June 2026
Menu
Gut Metabolic

A food-science magazine on the gut microbiome and metabolic health — every claim sourced.

Feature

Bifidobacterium Lactis B420 and Body Fat: What the Trial Shows

A 225-person, 6-month RCT found B420 cut body fat ~4% — but the headline result came from a post-hoc analysis. An honest look at the evidence.

By Priya Raman

Nutrition & Microbiome Editor ·

Bifidobacterium animalis subsp. lactis 420 — sold as "B420" — is the rare weight-management probiotic that was tested in a properly sized, six-month randomized trial. That alone puts it ahead of most "metabolic" probiotics, which lean on tiny studies or animal data. The trial found that B420 reduced body fat. But the honest version of that headline has an asterisk worth understanding before you buy anything: the clean statistical win came from a post-hoc (after-the-fact) analysis, not the trial's pre-specified primary outcome.

The trial: 225 adults, six months, four groups

The pivotal study (Stenman and colleagues, 2016) randomized 225 overweight and obese but otherwise healthy adults to one of four daily treatments for six months: placebo (microcrystalline cellulose), the prebiotic fiber Litesse (polydextrose) alone, B420 alone, or B420 plus the fiber 1. The design is exactly what you want: adequately powered, double-blind, and long enough to see body-composition change rather than just a marker blip.

Evidence summary

  • Body fat mass reduction (~4%, 6 months)Moderate evidence

    225-person RCT; significant in per-protocol/post-hoc analysis (P=0.002), not the ITT primary (P=0.28).

  • B420 + prebiotic fiber synergy for fat lossWeak evidence

    Fiber alone didn't reduce fat; combination didn't clearly beat B420 alone in this trial.

  • Akkermansia / gut-barrier mechanismWeak evidence

    Mouse data for Akkermansia and liver; human link is a zonulin association, not a proven pathway.

  • Generic 'B. lactis' (no strain code) for weightNone evidence

    Effects are strain-specific; only the defined 420 strain at 10^10 CFU/day was studied.

Grades reflect the Stenman 2016 trial. The fat-mass row is moderate because the significant effect was post-hoc, not the pre-specified primary outcome.

Here's the nuance. In the trial's primary (intention-to-treat) analysis, B420 alone reduced relative body fat mass by about 3% versus placebo, but that did not reach statistical significance (P=0.28). In a per-protocol/post-hoc analysis — restricted to people who actually completed the protocol — B420 reduced body fat mass by about 4% versus placebo, and that was significant (P=0.002) 1. The reductions were most pronounced in the abdominal region, and a smaller waist measurement accompanied the fat-mass change. A post-hoc significant result is a real signal, but it sits a notch below a pre-planned primary endpoint — it's the kind of finding that earns a moderate, not strong, grade and ideally wants independent replication.

Did the fiber help? Read this carefully

The product is often marketed as "best with prebiotic fiber," and the synergy story is biologically reasonable — but this particular trial doesn't cleanly prove it. Fiber (polydextrose) alone did not reduce body fat in the study, and adding fiber to B420 did not clearly beat B420 on its own for the fat-mass outcome 1. So the honest read is: B420 carried the effect here, and the prebiotic-pairing benefit is more a mechanistic expectation than a result this trial demonstrated. A separate randomized study of the same probiotic-and-fiber approach in overweight adults found it altered the gut microbiota and metabolism, supporting the mechanism without overturning the modest body-composition picture 2.

The Akkermansia and metabolic mechanism — mostly from mice

Why might B420 affect fat at all? The mechanistic work points toward the gut barrier and a now-famous "good" bacterium, Akkermansia muciniphila. In an obesogenic mouse model, polydextrose with or without B420 increased the prevalence of Akkermansia and improved liver health 3, and in diabetic mice B420 plus polydextrose improved the efficacy of antidiabetic drugs 4. Akkermansia itself has real — if early — human metabolic credentials: a proof-of-concept study in overweight and obese volunteers found supplementing with it improved several metabolic markers 5. (We cover that strain in depth in Akkermansia and metabolic health.) The throughline is gut-barrier integrity: the B420 trial linked its fat-mass effect to serum zonulin, a marker of intestinal permeability 1. That's a coherent story — but note the Akkermansia/liver and drug-efficacy pieces are rodent data, and rodent metabolism translates to humans inconsistently.

Key takeaway

What B420 can and can't do

  • A genuine 225-person, 6-month RCT showed roughly a 4% body-fat-mass reduction — strong design for a probiotic.
  • But that significant result came from a post-hoc analysis; the pre-specified primary outcome wasn't significant.
  • The 'works best with fiber' pitch wasn't actually proven for fat loss in the trial — B420 carried the effect.
  • It's strain-specific: only B. animalis subsp. lactis 420 at 10^10 CFU/day was studied — buy the strain code, not just 'B. lactis.'

The strain-specificity rule still applies

As with every probiotic, the evidence is for one defined strain at one dose — B. animalis subsp. lactis 420 at 10^10 CFU/day. A bottle that lists only "Bifidobacterium lactis" (a common species in countless yogurts and blends) is not the studied product. This is exactly why the category-wide meta-analysis of probiotics for weight finds only a small average effect of about −0.6 kg: it pools many strains, most of which aren't B420 6. Buy the strain code, or you're paying for the marketing, not the trial. We keep that discipline across our best probiotics for weight loss review and the best metabolic probiotic hub.

Safety and honest expectations

For most healthy people, B420 is well tolerated. The general probiotic-safety caveat applies — rare bloodstream infections are documented in immunocompromised or critically ill patients, so anyone with a serious medical condition should consult a clinician first 7. As for expectations: a ~4% reduction in body fat mass over six months (in the favorable analysis) is a genuine, useful nudge, but it is not dramatic weight loss and it is dwarfed by what GLP-1 medications achieve. The stronger metabolic lever remains fermentable fiber feeding your whole microbial community, which we explain in our pillar on the gut–metabolism connection, and the broader probiotic picture is in do probiotics help weight and metabolism?. For where the prebiotic-plus-probiotic logic does and doesn't hold up, see prebiotics vs probiotics vs postbiotics.

The honest bottom line

B420 is one of the better-evidenced weight-management probiotics: a real, six-month, 225-person randomized trial showing a roughly 4% reduction in body fat mass. The catch is that the clean statistical win was a post-hoc analysis rather than the pre-specified primary outcome, the prebiotic-fiber "synergy" wasn't actually demonstrated for fat loss in that trial, and much of the supporting mechanism is mouse data. Treat B420 as a modest, strain-specific tool — buy the exact strain and dose, keep expectations realistic, and build it on top of a fiber-rich diet rather than in place of one.

A 225-person, 6-month RCT found B420 cut body fat ~4% — but the headline result came from a post-hoc analysis. An honest look at the evidence.
Gut Metabolic — the short version

Reader questions

Does Bifidobacterium lactis B420 actually reduce body fat?

In a 225-person, 6-month randomized trial, B420 reduced body fat mass by about 4% versus placebo — but that significant result came from a per-protocol/post-hoc analysis; the trial's pre-specified primary outcome was not statistically significant. It's a real but modest, asterisked effect.

Do you need to take B420 with prebiotic fiber?

The product is marketed that way, but the pivotal trial didn't prove it for fat loss: fiber alone didn't reduce body fat, and combining it with B420 didn't clearly beat B420 alone. The fiber-synergy idea is a mechanism, not a demonstrated result in that study.

How does B420 raise Akkermansia?

The Akkermansia and liver-health findings come mainly from mouse studies of B420 with polydextrose. In humans, the trial linked B420's fat effect to lower zonulin, a gut-permeability marker — a coherent but not fully proven pathway.

Will any Bifidobacterium lactis supplement work like B420?

No. Probiotic effects are strain-specific. Only the defined B. animalis subsp. lactis 420 strain at 10^10 CFU per day was studied. A product listing just 'B. lactis' without the 420 strain code is not the tested product.

Sources

  1. Stenman LK, Lehtinen MJ, Meland N, et al. (2016). Probiotic With or Without Fiber Controls Body Fat Mass, Associated With Serum Zonulin, in Overweight and Obese Adults — Randomized Controlled Trial. EBioMedicine. https://pubmed.ncbi.nlm.nih.gov/27810310/
  2. Hibberd AA, Yde CC, Ziegler ML, et al. (2019). Probiotic or synbiotic alters the gut microbiota and metabolism in a randomised controlled trial of weight management in overweight adults. Beneficial Microbes. https://pubmed.ncbi.nlm.nih.gov/30525950/
  3. Yde CC, Jensen HM, Christensen N, et al. (2021). Polydextrose with and without Bifidobacterium animalis ssp. lactis 420 drives the prevalence of Akkermansia and improves liver health in a multi-compartmental obesogenic mice study. PLoS One. https://pubmed.ncbi.nlm.nih.gov/34855861/
  4. Stenman LK, Waget A, Garret C, et al. (2015). Probiotic B420 and prebiotic polydextrose improve efficacy of antidiabetic drugs in mice. Diabetology & Metabolic Syndrome. https://pubmed.ncbi.nlm.nih.gov/26366205/
  5. Depommier C, Everard A, Druart C, et al. (2019). Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine. https://pubmed.ncbi.nlm.nih.gov/31263284/
  6. Borgeraas H, Johnson LK, Skattebu J, Hertel JK, Hjelmesæth J (2018). Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. Obesity Reviews. https://pubmed.ncbi.nlm.nih.gov/29047207/
  7. Doron S, Snydman DR (2015). Risk and safety of probiotics. Clinical Infectious Diseases. https://pubmed.ncbi.nlm.nih.gov/25922398/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.

Also in this issue